Online citations, reference lists, and bibliographies.
← Back to Search

First‐line Ritonavir/indinavir 100/800 mg Twice Daily Plus Nucleoside Reverse Transcriptase Inhibitors In A German Multicentre Study: 48‐week Results

E. Voigt, A. Wickesberg, J. Wasmuth, P. Gute, L. Locher, B. Salzberger, A. Wöhrmann, A. Adam, L. Weitner, J. Rockstroh
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
To evaluate safety and efficacy of the protease inhibitor combination ritonavir/indinavir 100/800 mg twice daily plus 2–3 nucleoside reverse transcriptase inhibitors (NRTI) in antiretroviral‐naive patients.
This paper references
10.1093/CLINIDS/17.4.802
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
K. Castro (1992)
Revised Classi®cation System for HIV-Infection and Expanded Surveillance Case De®nition for AIDS among Adolescents and Adults
Anon (1992)
10.1056/NEJM199604183341602
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
A. Collier (1996)
10.1038/nm0796-760
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
A. Molla (1996)
Treatment of human immunode®ciency virus infection with saquinavir, zidovudine, and zalcitabine
A C Collier (1996)
10.1056/NEJM199709113371102
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
R. Gulick (1997)
10.1128/AAC.41.3.654
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
D. Kempf (1997)
10.1056/NEJM199709113371101
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
S. Hammer (1997)
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunode®ciency virus infection and CD4 cell counts of 200 per cubic millimeter or less
S M Hammer (1997)
10.1097/00002030-199818000-00003
Changes in renal function associated with indinavir
K. Boubaker (1998)
10.1128/AAC.42.11.2784
Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers
Ann Hsu (1998)
10.1016/S0140-6736(97)04161-5
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
D. W. Cameron (1998)
10.1097/00002030-199901140-00002
Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.
O. Kirk (1999)
10.1097/00002030-200006160-00015
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals
J. Rockstroh (2000)
10.1016/S0140-6736(00)02854-3
Adverse effects of antiretroviral therapy
A. Carr (2000)
10.1177/135965350000500402
Effectiveness and Pitfalls of Initial Highly Active Antiretroviral Therapy in HIV-Infected Patients in Routine Clinical Practice
Ana Moreno (2000)
10.1001/JAMA.283.2.205
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
D. Descamps (2000)
Differences in viral load outcomes at 90, 180 and 170 days in protease inhibitor naive patients treated with dual versus single therapy
D Butcher (2000)
Austrian guidelines for antiretroviral therapy in HIV-infection
Anon (2000)
Mechanisms of virological failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
D Descamps (2000)
10.1097/00042560-200103010-00003
A Retrospective, Cohort‐Based Survey of Patients Using Twice‐Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy
D. Burger (2001)
10.1128/AAC.45.10.2710-2715.2001
Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers
Alfred J. Saah (2001)
Ef®cacy and safety of twice daily ®rst-line ritonavir/ indinavir plus double nucleoside combination therapy in HIV-infected individuals
J. Rockstroh
Ritonavir (RTV)/ indinavir (IDV) (100/400 mg bid): a simple, effective and well tolerated PI containing regimen
C Katlama



This paper is referenced by
Design and Synthesis of potent benzimidazolone HIV Non-nucleoside reverse transcriptase inhibitors
Nicole Pribut (2018)
10.1007/978-1-4939-0694-9_28
HIV protease inhibitor resistance
A. Wensing (2017)
Exploring the Impact of Antiretroviral Drugs on the Cell-to-Cell spread of HIV-1
B. Titanji (2015)
10.1111/hiv.12119
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)
I. Williams (2014)
HIV-1 in the United Kingdom: population dynamics and genetic evolution
G. Foster (2014)
10.1093/cid/ciu617
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.
G. Lucas (2014)
10.1111/j.1468-1293.2012.01029.x
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012
I. Williams (2012)
10.2217/FVL.11.34
Lopinavir: the old champion
E. Nunes (2011)
10.1177/1545109710385121
Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India
Atul K Patel (2011)
10.1016/j.antiviral.2009.10.003
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.
A. Wensing (2010)
10.1089/aid.2009.0105
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
J. Miró (2010)
10.1128/AAC.01301-07
Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy
J. Ghosn (2008)
10.1517/14740338.7.4.389
Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients
M. Harris (2008)
10.1097/MCC.0b013e3283186f43
Acute kidney injury in patients with human immunodeficiency virus infection
Scott D. Cohen (2008)
COMPARISONOFINDINAVIR+RITONAVIR600+100 mgVS. 400+100 mg BID COMBINATIONSINHIV1-INFECTEDPATIENTSGUIDEDBY THERAPEUTICDRUGMONITORING
E. Rodermann (2007)
10.1007/s00228-007-0343-z
Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity
J. Wasmuth (2007)
10.1089/AID.2006.0038
Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
C. Danel (2007)
10.1310/hct0706-309
Cost to Achieve an Undetectable Viral Load Using Recommended Antiretroviral Regimens
Rituparna Basu (2006)
10.1097/01.qai.0000230522.86964.5d
Effectiveness of Low-Dose Indinavir/Ritonavir at 400/100 mg Twice a Day With 2 Nucleoside Reverse Transcriptase Inhibitors in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-Infected Patients in India: 1-Year Follow-up
A. Patel (2006)
AVT-904 Boyd
M. Boyd (2006)
10.1177/135965350601100212
Boosted versus Unboosted Indinavir with Zidovudine and Lamivudine in Nucleoside Pre-Treated Patients: A Randomized, Open-Label Trial with 112 Weeks of Follow-Up (HIV-Nat 005)
M. Boyd (2006)
10.1097/01.QAI.0000230523.94588.85
Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy.
A. Dzwonek (2006)
10.1111/j.1468-1293.2005.00255.x
Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily
D. Konopnicki (2005)
10.1016/S0755-4982(05)84227-7
Effets indésirables induits par les traitements antirétroviraux
M. Lagrange-Xelot (2005)
10.1111/J.1523-1755.2005.67096.X
HAART-related nephropathies in HIV-infected patients.
E. Daugas (2005)
HIV Medicine 2005
C. Hoffmann (2005)
10.1007/978-3-0348-7869-2_2
A perspective of the history of HAART
D. Konopnicki (2004)
10.1097/00126334-200411010-00004
Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals
E. Acosta (2004)
Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome.
S. Lowe (2004)
10.1177/135965350400900209
Comparison of Two Reduced-Dose Regimens of Indinavir (600 Mg Vs 400 Mg Twice Daily) and Ritonavir (100 Mg Twice Daily) in Healthy Volunteers (Coredir)
J. Wasmuth (2004)
Application of Pharmacokinetics to Improve Antiretroviral Treatment.
R. Aarnoutse (2003)
10.1177/135965350300800607
Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals
C. Duvivier (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar